{"filing":{"accession_number":"0001490978-26-000059","cik":"0001490978","ticker":"SDGR","company_name":"Schrodinger, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"sdgr-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097826000059/sdgr-20260629.htm"},"events":[{"id":14670,"run_id":13068,"accession_number":"0001490978-26-000059","anchor_item_number":"7.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The disclosure reports receipt of approximately $57 million in cash from Eli Lilly's acquisition of Ajax Therapeutics, a company co-founded by Schrödinger, plus eligibility for additional milestone-based payments. This is a financial event involving a material cash inflow and contingent consideration, but does not fit the specific M\u0026A categories (which typically apply when the registrant itself is acquired or makes an acquisition) since Schrödinger is receiving proceeds from a third-party acquisition of an affiliate. The event is material to investors as it represents a significant capital receipt and future contingent cash flows.","company_name":"Schrodinger, Inc.","ticker":"SDGR","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12165,"accession_number":"0001490978-26-000059","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports receipt of approximately $57 million in cash from Eli Lilly's acquisition of Ajax Therapeutics, a company co-founded by Schrödinger, plus eligibility for additional milestone-based payments. This is a financial event involving a material cash inflow and contingent consideration, but does not fit the specific M\u0026A categories (which typically apply when the registrant itself is acquired or makes an acquisition) since Schrödinger is receiving proceeds from a third-party acquisition of an affiliate. The event is material to investors as it represents a significant capital receipt and future contingent cash flows.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:31:39.222162+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12165,"accession_number":"0001490978-26-000059","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports receipt of approximately $57 million in cash from Eli Lilly's acquisition of Ajax Therapeutics, a company co-founded by Schrödinger, plus eligibility for additional milestone-based payments. This is a financial event involving a material cash inflow and contingent consideration, but does not fit the specific M\u0026A categories (which typically apply when the registrant itself is acquired or makes an acquisition) since Schrödinger is receiving proceeds from a third-party acquisition of an affiliate. The event is material to investors as it represents a significant capital receipt and future contingent cash flows.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:31:39.222162+00:00","company_name":"Schrodinger, Inc.","ticker":"SDGR","filing_date":"2026-06-29"}]}